Literature DB >> 28792647

Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition.

Dominique Cazals-Hatem1, Lore Billiauws2, Pierre-Emmanuel Rautou3,4,5, Vanessa Bondjemah2, Nicolas Poté1,4,5, Olivier Corcos2, Valérie Paradis1,4,5, Francisca Joly2,4,5.   

Abstract

BACKGROUND & AIMS: Intestinal failure-associated liver disease is rare in adults and risk factors are unclear. The aim of this study was to determine risk factors of liver fibrosis in adults receiving home parenteral nutrition for intestinal failure and its impact on survival.
METHODS: We retrospectively analysed patients with irreversible intestinal failure who underwent a liver biopsy between 2000 and 2013. Significant liver fibrosis was defined as ≥F2 according to NASH-CRN score.
RESULTS: Thirty-two patients (46 years [29-60]) underwent liver biopsy 55 months (9-201) after beginning parenteral nutrition. Twenty-six patients (81%) had a short bowel (gut < 200 cm), including 12 (37%) with an ultra-short bowel (gut < 20 cm). Eighteen patients (56%) had liver fibrosis (4 F2, 10 F3, 4 F4), associated with steatohepatitis (72%) and/or cholestasis (17%). Factors associated with occurrence of liver fibrosis included ultra-short bowel (83% vs 13% at 60 months; P < .001), alcohol consumption (73% vs 33% at 60 months; P < .001) and diabetes (80% vs 34% at 60 months; P = .01). Home parenteral nutrition composition, quantity, or duration, episodes of sepsis, abandoned bowel segment were not associated with fibrosis. Ultra-short bowel [risk ratio 12.4, P < .001] and alcohol consumption [risk ratio 7.4, P = .009] independently predicted the development of liver fibrosis on multivariate analysis. After a median follow-up of 118 months (72-155), survival was poorer in patients who developed liver fibrosis than in those without (59% vs 92% at 120 months; P = .02).
CONCLUSION: An ultra-short bowel and alcohol consumption are independent risk factors for liver fibrosis in adults requiring HPN.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  home parenteral nutrition; intestinal failure; short bowel syndrome; steatohepatitis

Mesh:

Year:  2017        PMID: 28792647     DOI: 10.1111/liv.13545

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  Hepatobiliary Manifestations of Short Bowel Syndrome and Intestinal Failure-Associated Liver Disease.

Authors:  Jennifer Wang; Dejan Micic
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

2.  Managing intestinal failure in inflammatory bowel disease - 'when the drugs don't work'.

Authors:  James Morgan; Ashley Bond; Cecil Kullu; Sreedhar Subramanian; Martyn Dibb; Philip J Smith
Journal:  Frontline Gastroenterol       Date:  2020-06-19

Review 3.  The Long and Short of IT: intestinal failure-associated liver disease (IFALD) in adults-recommendations for early diagnosis and intestinal transplantation.

Authors:  Jeremy Mark Woodward; Dunecan Massey; Lisa Sharkey
Journal:  Frontline Gastroenterol       Date:  2019-02-12

4.  Short-Bowel Syndrome: Epidemiology, Hospitalization Trends, In-Hospital Mortality, and Healthcare Utilization.

Authors:  Mohamed Tausif Siddiqui; Wael Al-Yaman; Amandeep Singh; Donald F Kirby
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-12-17       Impact factor: 3.896

5.  Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study.

Authors:  Konstantinos C Fragkos; María Claudia Picasso Bouroncle; Shankar Kumar; Lucy Caselton; Alex Menys; Alan Bainbridge; Stuart A Taylor; Francisco Torrealdea; Tomoko Kumagai; Simona Di Caro; Farooq Rahman; Jane Macnaughtan; Manil D Chouhan; Shameer Mehta
Journal:  Nutrients       Date:  2020-07-19       Impact factor: 5.717

Review 6.  New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.

Authors:  Fotios S Fousekis; Ioannis V Mitselos; Dimitrios K Christodoulou
Journal:  Saudi J Gastroenterol       Date:  2021 Jan-Feb       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.